GlassScriptPhysician profile
Zoltan Mocsary
NPI 1306843966
$18,374.76
in general payments reported to CMS, 2019-2025
70 companies · $3,973 in 2025
The $3,973 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,088 · 2020: $2,154 · 2021: $2,905 · 2022: $2,210 · 2023: $2,771 · 2024: $2,273 · 2025: $3,973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,989 · Education: $28.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,989.04 |
| Education | $28.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,394.97 | 2021-2025 | |
| Ucb, INC. | $1,393.11 | 2019-2025 | Rystiggo, Fintepla, Briviact |
| Biogen, INC. | $1,228.35 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Novartis Pharmaceuticals Corporation | $1,148.30 | 2019-2025 | |
| Eisai INC. | $787.51 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $784.75 | 2019-2025 | Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $715.68 | 2019-2022 | |
| Kyowa Kirin, INC. | $611.53 | 2019-2023 | Nourianz |
| Lilly USA, LLC | $517.89 | 2019-2025 | Emgality, Kisunla, Reyvow |
| Neurocrine Biosciences, INC. | $503.44 | 2022-2024 | Ingrezza, Ongentys |
| Amneal Pharmaceuticals LLC | $480.08 | 2021-2025 | Crexont, Rytary |
| Pfizer INC. | $440.68 | 2019-2025 | |
| Tg Therapeutics, INC. | $429.55 | 2025 | |
| Lundbeck LLC | $371.71 | 2021-2025 | Vyepti |
| Acadia Pharmaceuticals INC | $358.64 | 2019-2025 | Nuplazid |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zoltan Mocsary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.